Generic Pharma Industry
Published July 18, 2020, 7:10 a.m.
in blog Invest
- Opiod settlement reduces risks
MYL - aggressive CEO
5.5f 0% 1yr=-35%
- hurt by "bought rights to EpiPen then goofed price $50>$600"
- Generic epipen TEVA competitor
- Trades at 10% discount to even Teva
- Acqs to boost growth eg Meda'16 at 2x mcap - myl-20% since-30%
? generic approval to compete Advair for Asthma of gsk
WS projects 10% eps '19 8% in 2020
TEVA m12b - lots of debt
- hurt bad - but look forwart - ?how realistic
RDY m7.4b y0.6% ROA12% DE=0.2
TARO m3b ROA=13% DE=0
There are no comments yet
Add new comment
There are no similar posts yet.